Flexion Therapeutics
208 articles with Flexion Therapeutics
-
From artificial intelligence breakthroughs to at-home genetic testing, here are some ways COVID-19 has changed the biopharma industry and what we may see in the near future.
-
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
10/11/2021
Pacira BioSciences, Inc. and Flexion Therapeutics, Inc. (Nasdaq: FLXN) today announced a definitive agreement pursuant to which Pacira will acquire Flexion for $8.50 per share in cash, plus one non-tradeable contingent value right (CVR) worth up to $8.00 per share in cash.
-
Zilretta is the first treatment approved by the U.S. FDA for OA knee pain that uses extended-release microsphere technology.
-
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 01, 2021
10/1/2021
Flexion Therapeutics, Inc. announced equity inducement grants to three new employees consisting of 6,315 restricted stock units.
-
It's a New Hybrid World for Biopharma
9/20/2021
One constant throughout the conversation is that the industry is at a different stage of adapting to the “new normal.” -
Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
9/8/2021
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in a virtual analyst-led fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.
-
Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference
9/3/2021
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2021 Virtual Healthcare Conference.
-
Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the Knee
9/2/2021
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the American Academy of Orthopaedic Surgeons (AAOS) included ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in its updated evidence-based clinical practice guidelines for the management of osteoarthritis (OA) of the knee.
-
Flexion Therapeutics Announces Expansion of Phase 1b Trial Investigating FX301 for the Management of Post-Operative Pain
8/25/2021
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the expansion of the Phase 1b randomized, double-blind, placebo-controlled trial of FX301 in patients undergoing bunionectomy.
-
Clinical Catch-Up: August 9-13
8/16/2021
There was plenty of clinical trial updates last week. Here’s a look. -
Flexion Therapeutics Announces Publication of Results from Phase 2 Pharmacokinetics (PK) and Safety Study of ZILRETTA® in Shoulder Osteoarthritis (OA)
8/9/2021
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the results from the randomized, open-label, Phase 2 pharmacokinetic (PK) trial of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) were published in Drugs in R&D.
-
Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
8/4/2021
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended June 30, 2021.
-
Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021
7/29/2021
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, August 4, 2021 at 4:30 p.m. ET.
-
Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors
7/12/2021
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Utpal Koppikar, Chief Financial Officer of Atara Biotherapeutics, to its Board of Directors.
-
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 02, 2021
7/2/2021
Flexion Therapeutics, Inc. announced equity inducement grants to five new employees consisting of 20,440 restricted stock units.
-
Flexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference
6/14/2021
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2021 Raymond James Human Health Innovation Conference.
-
Flexion Therapeutics Announces Appointment of William T. Andrews, M.D., F.A.C.P., as Chief Medical Officer
6/9/2021
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that William T. Andrews, M.D., F.A.C.P., will join the company as Chief Medical Officer (CMO), effective July 1, 2021.
-
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 04, 2021
6/4/2021
Flexion Therapeutics, Inc. announced equity inducement grants to five new employees consisting of 8,510 restricted stock units.
-
Flexion Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference
6/2/2021
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference.
-
Flexion Therapeutics to Present at the RBC Capital Markets 2021 Virtual Global Healthcare Conference
5/13/2021
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the RBC Capital Markets 2021 Virtual Global Healthcare Conference.